Cryptocurrency investment firm Techemy Capital has announced the launch of its Holistic ETH-BTC portfolio in partnership with Enzyme Finance (formerly Melon Protocol).
The portfolio is powered by Brave New Coin, while it also uses Techemy’s long and short trading strategies to maximise exposure to Bitcoin and Ethereum price action.
It quantifies bullish or bearish conditions to add or subtract from each investor’s starting position, based on an assessment of on-chain activity, token age spent, and technical analysis.
The portfolio is powered by Enzyme, an Ethereum-based infrastructure for on-chain asset management. Enzyme connects fund managers to a pool of potential investors, making it easier to create a community.
Rotational assets in the portfolio include Wrapped Bitcoin (WBTC), Ethereum (ETH), USD Coin (USDC), Inverse ETH (iETH) and Inverse BTC (iBTC).
Paraswap – $MLN farming begins today!
TL;DR; Trades via @paraswap will be partially subsidised with some $MLN tokens for a week by the exchange aggregator for Enzyme. Find out more in this blog post 👇🏾 https://t.co/QgMzil8j4e
— Enzyme Finance (@enzymefinance) February 10, 2021
The inverse assets allow Techemy’s team of traders to effectively short either Bitcoin or Ethereum depending on market conditions.
Techemy is able to access deep liquidity across the entire Ethereum network thanks to Enzyme’s integration with Paraswap, a Decentralised Exchange aggregator that optimises order routing and minimises slippage.
“Following the exceptional performance of Techemy Capital’s private DeFi Portfolio in 2020, we are excited to open this product through Enzyme to the broader investor community,” said Fran Strajnar, Founder of Techemy Capital and Brave New Coin. “We are looking forward to working with Enzyme and our growing number of exchange partners to deliver the highest-grade digital asset and DeFi investment products.”
For more news, guides and cryptocurrency analysis, click here.